Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MTOR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MTOR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MTOR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MTOR_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190303419 | Oral cavity | EOLP | regulation of response to wounding | 38/2218 | 167/18723 | 5.06e-05 | 6.58e-04 | 38 |
GO:000762317 | Oral cavity | EOLP | circadian rhythm | 45/2218 | 210/18723 | 5.24e-05 | 6.79e-04 | 45 |
GO:00325164 | Oral cavity | EOLP | positive regulation of phosphoprotein phosphatase activity | 10/2218 | 21/18723 | 5.45e-05 | 7.01e-04 | 10 |
GO:190179626 | Oral cavity | EOLP | regulation of signal transduction by p53 class mediator | 25/2218 | 93/18723 | 5.69e-05 | 7.24e-04 | 25 |
GO:003083822 | Oral cavity | EOLP | positive regulation of actin filament polymerization | 26/2218 | 99/18723 | 6.27e-05 | 7.87e-04 | 26 |
GO:00023662 | Oral cavity | EOLP | leukocyte activation involved in immune response | 55/2218 | 275/18723 | 6.32e-05 | 7.90e-04 | 55 |
GO:004308714 | Oral cavity | EOLP | regulation of GTPase activity | 66/2218 | 348/18723 | 6.92e-05 | 8.55e-04 | 66 |
GO:00022852 | Oral cavity | EOLP | lymphocyte activation involved in immune response | 42/2218 | 194/18723 | 7.17e-05 | 8.82e-04 | 42 |
GO:000218324 | Oral cavity | EOLP | cytoplasmic translational initiation | 13/2218 | 34/18723 | 7.26e-05 | 8.88e-04 | 13 |
GO:006104117 | Oral cavity | EOLP | regulation of wound healing | 32/2218 | 134/18723 | 7.29e-05 | 8.89e-04 | 32 |
GO:004259422 | Oral cavity | EOLP | response to starvation | 42/2218 | 197/18723 | 1.03e-04 | 1.17e-03 | 42 |
GO:003530612 | Oral cavity | EOLP | positive regulation of dephosphorylation | 18/2218 | 59/18723 | 1.05e-04 | 1.19e-03 | 18 |
GO:003367419 | Oral cavity | EOLP | positive regulation of kinase activity | 82/2218 | 467/18723 | 1.58e-04 | 1.68e-03 | 82 |
GO:00609986 | Oral cavity | EOLP | regulation of dendritic spine development | 18/2218 | 61/18723 | 1.69e-04 | 1.78e-03 | 18 |
GO:004592716 | Oral cavity | EOLP | positive regulation of growth | 51/2218 | 259/18723 | 1.72e-04 | 1.79e-03 | 51 |
GO:190121423 | Oral cavity | EOLP | regulation of neuron death | 60/2218 | 319/18723 | 1.83e-04 | 1.87e-03 | 60 |
GO:003166923 | Oral cavity | EOLP | cellular response to nutrient levels | 44/2218 | 215/18723 | 1.92e-04 | 1.96e-03 | 44 |
GO:00105919 | Oral cavity | EOLP | regulation of lamellipodium assembly | 14/2218 | 42/18723 | 2.15e-04 | 2.15e-03 | 14 |
GO:003030715 | Oral cavity | EOLP | positive regulation of cell growth | 36/2218 | 166/18723 | 2.19e-04 | 2.18e-03 | 36 |
GO:003166725 | Oral cavity | EOLP | response to nutrient levels | 82/2218 | 474/18723 | 2.59e-04 | 2.52e-03 | 82 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MTOR | SNV | Missense_Mutation | novel | c.7184A>G | p.Asn2395Ser | p.N2395S | P42345 | protein_coding | tolerated(1) | possibly_damaging(0.703) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
MTOR | SNV | Missense_Mutation | | c.7498N>T | p.Ile2500Phe | p.I2500F | P42345 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-A8-A06Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
MTOR | SNV | Missense_Mutation | rs769877976 | c.25G>A | p.Ala9Thr | p.A9T | P42345 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.835) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
MTOR | SNV | Missense_Mutation | novel | c.6287N>T | p.Asp2096Val | p.D2096V | P42345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | novel | c.3142A>C | p.Ile1048Leu | p.I1048L | P42345 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | novel | c.5276N>G | p.Leu1759Arg | p.L1759R | P42345 | protein_coding | tolerated(0.51) | probably_damaging(0.995) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
MTOR | SNV | Missense_Mutation | | c.397N>G | p.Leu133Val | p.L133V | P42345 | protein_coding | deleterious(0) | possibly_damaging(0.563) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
MTOR | SNV | Missense_Mutation | | c.4835N>C | p.Arg1612Pro | p.R1612P | P42345 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
MTOR | SNV | Missense_Mutation | novel | c.3722N>G | p.Gln1241Arg | p.Q1241R | P42345 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | | c.7162N>C | p.Glu2388Gln | p.E2388Q | P42345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | QUINACRINE | QUINACRINE | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | inhibitor | BEZ235 | DACTOLISIB | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | TCMDC-125575 | CHEMBL587620 | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | PERPHENAZINE | PERPHENAZINE | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | PAZOPANIB | PAZOPANIB | 24625776 |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | inhibitor | 249565693 | | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | CAFFEIC ACID PHENETHYL ESTER | CAFFEIC ACID PHENETHYL ESTER | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | AZD2014 | VISTUSERTIB | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | GDC-0980/RG7422 | | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | | EVEROLIMUS | EVEROLIMUS | 24625776,25295501 |